事实证据 1
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
PR Newswire news releases · 2026-10-07 19:08
查看证据
- 公司披露PR Newswire news releases2026-10-07 19:08
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
查看来源